AI Stock Memo: ANRO - Alto Neuroscience - RankAlpha

ANRO

Rating neutralAI Memo

Alto Neuroscience

As of 2026-04-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

ALTO-207 Phase 2b trial initiation in TRD • 2026-06-30

Expected move: +13%

Biggest risk

The bearish view is that the April 1 ALTO-101 miss narrows the thesis to a handful of still-unproven programs, increases dependence on ALTO-207 execution, and leaves the stock vulnerable to any enrollment, start-up, or data slippage in 2026 [#8-K-2026-04-01].

Invalidation

Break below $14 or thesis failure.

What would change my mind?

The bullish view is that the March financing and roughly $275 million pro forma cash position buy enough runway to let ALTO-207, ALTO-300, and ALTO-100 reset sentiment after the ALTO-101 setback, with ALTO-207 now the lead value driver and potentially the clearest rerating path [#8-K-2026-04-01] [#10-K-2026-03-16].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-18

Base target

$24

p=45%

Bull target

$40

p=25%

Bear target

$14

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ALTO-300 Phase 2b MDD topline data
ALTO-100 Phase 2b bipolar depression topline data
The bullish view is that the March financing and roughly $275 million pro forma cash position buy enough runway to let ALTO-207, ALTO-300, and ALTO-100 reset sentiment after the ALTO-101 setback, with ALTO-207 now the lead value driver and potentially the clearest rerating path [#8-K-2026-04-01] [#10-K-2026-03-16].

BearKey bullets

ALTO-101 failed to hit statistical significance on primary EEG and cognitive endpoints, reducing pipeline breadth.
Clinical timelines are management-guided and can slip, which would pressure a small-cap biotech with limited commercial fallback.
PIPE funding improves runway but adds dilution and raises execution expectations around capital deployment.

WatchKey bullets

ALTO-207 Phase 2b trial initiation in TRD

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $24 (p=45%)

Bull/Bear spread: +89% / -34%

Vs latest close: Bull +89% · Base +13% · Bear -34%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $24 (p=45%)Bear Target: $14 (p=30%)

Commentary

Sentiment looks cautious rather than broken: the April 1 ALTO-101 readout was a real setback, but the March financing materially reduced near-term balance-sheet risk and left Alto with multiple remaining data shots in 2026. Even so, the deterministic prior stays negative, and the thesis has become narrower and more monitoring-oriented until ALTO-207 starts on time and another program produces cleaner efficacy evidence [#8-K-2026-04-01] [#10-K-2026-03-16].

As of 2026-04-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ALTO-300 Phase 2b MDD topline data
ALTO-100 Phase 2b bipolar depression topline data

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$24 / p=45% prob

Bear Target (Scenario probability)

$14 / p=30% prob

Price $21 as of 2026-05-22

Nearest Scenario: Base (∆ 13%)

Targets vs latest close: Bull +89% · Base +13% · Bear -34%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
ALTO-207 Phase 2b trial initiation in TRD
Management said ALTO-207 remains the top priority and the Phase 2b trial is on track to start in 1H 2026, with PIPE proceeds intended to support development through a planned Phase 3 path and potential NDA submission [#10-K-2026-03-16] [#PR-2026-03-16-financing].
Prob 70.00% • Move 14.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ALTO-300 Phase 2b MDD topline data
2026-07-15
Alto guided to mid-2026 topline data for ALTO-300, one of the remaining near-term readouts after the ALTO-101 miss, so a clean signal could broaden the thesis beyond ALTO-207 while a miss would reinforce single-asset concentration [#10-K-2026-03-16].
Prob 55% • Move 24% • Priced-in 35%
ALTO-100 Phase 2b bipolar depression topline data
2026-11-15
Management still guides to 2H 2026 topline data for ALTO-100, giving ANRO a second independent 2026 clinical swing that can either restore pipeline depth or deepen the post-ALTO-101 narrowing of the story [#10-K-2026-03-16].
Prob 50% • Move 22% • Priced-in 30%

Risks

ALTO-101 failed to hit statistical significance on primary EEG and cognitive endpoints, reducing pipeline breadth.
Clinical timelines are management-guided and can slip, which would pressure a small-cap biotech with limited commercial fallback.
PIPE funding improves runway but adds dilution and raises execution expectations around capital deployment.
The equity story is now more concentrated in ALTO-207 and two 2026 Phase 2b readouts.

Peers

Symbol	Summary
ASMB	Loose small-cap clinical-stage biotech comparator by market cap; useful for financing and binary-readout risk framing, but not an indication match.
CRVS	Another loose sub-$1 billion clinical-stage biotech comparator where valuation is heavily driven by cash runway and upcoming trial outcomes rather than commercial revenue.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-18